- Home
- PENG vs ORIC Comparison
PENG vs ORIC Comparison
Compare PENG & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | ORIC |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 959.2M | 837.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PENG | ORIC |
|---|---|---|
| Price | $47.71 | $8.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $27.78 | $19.73 |
| AVG Volume (30 Days) | ★ 2.6M | 1.2M |
| Earning Date | 04-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.55 | N/A |
| Revenue Next Year | $16.14 | N/A |
| P/E Ratio | $87.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.04 | $4.65 |
| 52 Week High | $53.27 | $14.93 |
Technical Indicators
Market Signals| Indicator | PENG | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 79.39 | 36.45 |
| Support Level | $17.48 | $7.90 |
| Resistance Level | N/A | $11.22 |
| Average True Range (ATR) | 3.19 | 0.48 |
| MACD | 1.27 | -0.08 |
| Stochastic Oscillator | 71.60 | 9.02 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.